Clinical Trials Logo

Appendiceal Neoplasms clinical trials

View clinical trials related to Appendiceal Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05513183 Completed - Clinical trials for Colorectal Cancer Metastatic

Severe Neutropenia After HIPEC Using Mitomycin-C

Start date: May 20, 2021
Phase:
Study type: Observational

Mitomycin-C (MMC) is the most commonly used chemotherapeutic agent for hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) to treat colorectal cancer patients with peritoneal metastases. However, MMC has a side effect of myelosuppression. Particularly, severe neutropenia after CRS with HIPEC can be a life-threatening condition. Despite the postoperative risks of this side effect, the causes and risk factors for severe neutropenia after CRS followed by HIPEC is not identified so far. Therefore, in this study, we aimed to evaluate to evaluate clinical risk factors and pharmacologic properties after CRS with HIPEC using MMC in patients with colorectal cancer or appendiceal mucinous neoplasms with peritoneal metastases.

NCT ID: NCT05452382 Completed - Appendiceal Cancer Clinical Trials

Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal Adenocarcinoma

Start date: January 1, 2005
Phase:
Study type: Observational

A few studies investigated the predictors of overall survival in appendiceal adenocarcinoma. A SEER database analysis of 1404 patients with appendiceal adenocarcinoma found that older age, T4 tumors, N1-2 stage, poorly differentiated carcinoma, and distant metastasis were significantly predictive of poorer survival. Another small single-center study including 49 appendiceal cancer patients reported female gender and low-grade adenocarcinoma to be associated with increased overall survival. However, these previous analyses did not take into account some important prognosticators of survival such as patients' comorbidities and functional status, pathologic parameters such as lymphovascular invasion, and adjuvant systemic treatment. Therefore, we used the National Cancer Database (NCDB) to conduct a comprehensive analysis of the predictors of overall survival after surgical treatment of stage I-III appendiceal adenocarcinoma.

NCT ID: NCT04526886 Completed - Colorectal Cancer Clinical Trials

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)-type chemotherapy, while maintaining acceptable chemotherapy dose-intensity.

NCT ID: NCT03852693 Completed - Clinical trials for Neuroendocrine Tumors of the Appendix

Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix

SurvivApp
Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of the present project is to evaluate the frequency of distant metastases and clinically relevant relapse and mortality, respectively, of aNEN (Neuroendocrine Neoplasms of the Appendix) measuring 1 - 2 cm. The investigators hypothesize that the mortality rate of aNET (Neuroendocrine Tumors of the Appendix) measuring 1 - 2cm is less than 1%. Furthermore, the investigators hypothesize that regional lymph node metastases of aNET measuring 1 - 2 cm are clinically not relevant and are not associated with reduced survival. The investigators therefore hypothesize that oncological right-sided hemicolectomy has no impact on long-term survival after complete resection of aNET measuring 1 - 2 cm and that the malignant potential quo ad vitam of these tumors is lower than the risk of oncological hemicolectomy.

NCT ID: NCT03604653 Completed - Colorectal Cancer Clinical Trials

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Start date: May 15, 2018
Phase:
Study type: Observational

Patients with primary peritoneal cancer or secondary peritoneal cancers from stomach, colorectal, appendiceal, and gynecological primary origin will be screened by pathology and staging to see if they are eligible to undergo cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). To be eligible for the study, patients must be over 18 years of age, have appropriate pathology and stage with disease confined to the peritoneal cavity, have a good performance status, have laboratory values that fall within safe ranges to undergo an operation and receive intraperitoneal chemotherapy. The chemotherapeutic agent and dose will be assigned based on pathological diagnosis in accordance with current standard of care. Surgery will be performed with the goal of removing all visible tumor that may require removal of adjacent organs. Once only microscopic disease is present, the chemotherapy will be delivered directly into the peritoneum via intraperitoneal hyperthermia and perfusion device. This will continue for 90 minutes. Patients will be followed for tumor response, survival, toxicity, complications, quality of life, and tumor markers. They will have regular follow up visits with the surgeon, undergo routine surveillance imagings, and receive follow up phone calls periodically.

NCT ID: NCT03246321 Completed - Clinical trials for Colorectal Neoplasms

PIPAC for Peritoneal Metastases of Colorectal Cancer

CRC-PIPAC
Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC-OX) as a palliative monotherapy for patients with isolated unresectable colorectal peritoneal metastases.

NCT ID: NCT02963831 Completed - Colorectal Cancer Clinical Trials

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Start date: September 7, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1 (PD-L1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed epithelial ovarian cancer or metastatic colorectal cancer.

NCT ID: NCT02833753 Completed - Colorectal Cancer Clinical Trials

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I dose escalation study to determine how much chemotherapy can be safely administered into the abdomen while experiencing the fewest possible side effects.

NCT ID: NCT02489422 Completed - Depression Clinical Trials

Programs To Support You During Chemotherapy

PRO-YOU
Start date: August 2016
Phase: N/A
Study type: Interventional

This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy. Possible mediators such as psychological stress, circadian disruption, and inflammation, will also be explored.

NCT ID: NCT02374411 Completed - Sarcoma Clinical Trials

Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients

Start date: September 2014
Phase: N/A
Study type: Observational

The goal of this survey of international HIPEC (Hyperthermic Intraperitoneal Chemotherapy) surgeons is to determine their knowledge of and attitudes towards the nutritional support needs of HIPEC patients and what their practice patterns are with this patient population.